Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.
This is a single-arm, Phase II clinical study to explore the efficacy and safety of dalpiciclib combined with fluvestrant and compound gossypol acetate tablets in advanced HR-positive and HER2-negative breast cancer after CDK4/6 treatment failed.
Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed
DRUG: dalpiciclib; fluvestrant; compound gossypol acetate tablets
Objective Response Rate (ORR), ORR is defined as the percentage of patients who achieved a best overall response of Complete Response (CR) or Partial Response (PR), per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1) for target lesions as assessed by the Investigator: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters., up to 24 months
Progression-Free Survival (PFS), From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months., up to 24 months|Clinical Benefit Rate (CBR), Percentage of participants with complete response (CR) or partial response (PR) or stable disease (SD) lasting 24 weeks or longer as defined in RECIST v1.1., up to 24 months|Duration of Overall Response(DoR), Time from first recording to CR or PR to disease progression or all-cause death., up to 24 months|Time to response (TTR), TTR defined as the time from the date of the first dose of study treatment to the first objective tumor response when CR or PR is observed., up to 24 months|Overall survival (OS), Time to death from any cause from the date of first dose of study treatment, up to 24 months|adverse event(AE), Evaluation performed using the National Cancer Institute (NCI)- Standard for Common Terminology for Adverse Events (CTCAE)v.5.0., Throughout the experiment, assessed up to 24 months.
Exploratory endpoint, Correlation between the expression levels of LRPPRC and CDK6 and the efficacy of Dalpiciclib combined with Fulvestrant and Compound Gossyfol Acetate Tablets., Throughout the experiment, assessed up to 24 months.
Dalpiciclib: According to the standard dose, 150mg orally for three weeks and stop for one week.

Fluvestrant: At the standard dose, 500mg once every four weeks. A further 500mg dose two weeks after the first dose.

Compound gossypol acetate tablets: 20mg once a day.